June 2016, Volume 2, Issue 6

June 2016

Volume 2, Issue 6

This issue features an inside look at the National Cancer Moonshot Initiative and updates from the American Association for Cancer Research Annual Meeting.

Table of Contents

June 2016

Hank’s SMILE

Wednesday, June 1st, 2016
A look at the social side of medicine. In this edition, Jose A. Bufill, MD, shares the story of a patient who was helped...

Does this child have both beta and alpha thalassemia trait?

Wednesday, June 1st, 2016
Here's how readers responded to a You Make the Call question about a diagnosis of beta and alpha thalassemia trait. Disclaimer: ASH does not recommend...

Recommendations from My Bookshelf: Cutting for Stone by Abraham Verghese

Wednesday, June 1st, 2016
Have you ever been a stranger in a strange land? I thought I was when I moved from New England to Cleveland, where I had...

June 2016

ASH Introduces New Educational Series

Wednesday, June 1st, 2016
The ASH Impact Series is the Society’s newest educational offering, which provides free, on-demand content on key topics presented at the latest ASH annual...

Remembering Anthony Tartaglia, Announcing the ASH 2016 Physician–Scientist Career-Development Award Recipients, and more

Wednesday, June 1st, 2016
Anthony Tartaglia, MD, a prominent blood disease specialist and distinguished emeritus member of the American Society of Hematology, passed away on March 21, 2016,...

June 2016

Shooting for the Moon: Is the Cancer Moonshot a Long Shot?

Wednesday, June 1st, 2016
More than 50 years after President Kennedy declared the United States’ intent to go to the moon – “not because easy, but because...

Pulling Back the Curtain: Robert P. Gale, MD, PhD

Wednesday, June 1st, 2016
What was your first job? My first job was working in my family’s haute couture business in New York. I started delivering fabrics and, after...

June 2016

Does this child have both beta and alpha thalassemia trait?

Wednesday, June 1st, 2016
This month, William C. Mentzer, MD, offers his advice about a pediatric patient with possible beta and alpha thalassemia trait.I have a 6-year-old, Indian...

June 2016

AHCT Is an Option for Patients with Lymphoma and Treatment-Responsive HIV Infection

Wednesday, June 1st, 2016
Results from the BMT CTN 0803/AIDS Malignancy Consortium 0071 study debunk the myth that HIV-positive patients with lymphoma are unsuitable for autologous hematopoietic cell...

T Cell Therapy for Previously Treated Multiple Myeloma, Emicizumab in Hemophilia A Patients With...

Wednesday, June 1st, 2016
LEUKEMIA David Steensma, MD Dana-Farber Cancer Institute A Two-Arm Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients With Myelodysplastic Syndromes (MDS)...

Dasatinib Plus Low-Intensity Chemotherapy Results in Long-Term Survival for Older Patients with Ph+ ALL

Wednesday, June 1st, 2016
A long-term study focusing on older patients with Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) found that 96 percent of patients treated with a...

Pembrolizumab Granted Breakthrough Designation for Hodgkin Lymphoma

Wednesday, June 1st, 2016
The U.S. FDA granted breakthrough therapy designation for pembrolizumab – a humanized monoclonal anti-PD-1 therapy – for the treatment of patients with relapsed/refractory classic...

What To Call What We Treat, Part II: WHO Releases Updated Classification of...

Wednesday, June 1st, 2016
Advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias – thanks in part to gene-expression analyses and next-generation...

NCCN Updates Myeloma Diagnostic Criteria, Therapy Recommendations

Wednesday, June 1st, 2016
The National Comprehensive Cancer Network (NCCN) released its 2016 Clinical Practice Guidelines in Oncology for Multiple Myeloma, which includes several new treatment options and broadens...

FDA Approves Defibrotide for Patients who Develop Hepatic Veno-Occlusive Disease After Transplant

Wednesday, June 1st, 2016
The U.S. FDA approved defibrotide sodium for adults and children with hepatic veno-occlusive disease (VOD) with additional kidney or lung abnormalities after they have...

FDA Approves Venetoclax for Patients with CLL and Del17p

Wednesday, June 1st, 2016
The U.S. Food and Drug Administration (FDA) approved venetoclax for the treatment of patients with chronic lymphocytic leukemia (CLL) who harbor the 17p deletion...

International Cancer Genome Consortium for Medicine Launches

Wednesday, June 1st, 2016
The International Cancer Genome Consortium (ICGC) announced plans to launch the ICGC for Medicine (ICGCmed), a new phase of the consortium that will link...

Arsenic Trioxide Plus ATRA: A Better Option for Patients With Acute Promyelocytic Leukemia?

Wednesday, June 1st, 2016
The combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) could be a safer and more effective treatment option than ATRA and chemotherapy...

Corticosteroids Increase the Risk of Recurrent Thrombotic Events

Wednesday, June 1st, 2016
Patients with chronic inflammatory diseases, such as chronic obstructive pulmonary disease and asthma, are already at an increased risk for developing a first pulmonary...

Greater Survival and Response Rates with Bendamustine-Rituximab than Fludarabine-Rituximab in Patients with Non-Hodgkin Lymphoma...

Wednesday, June 1st, 2016
The combination of bendamustine and rituximab (BR) resulted in superior overall response rates (ORR) and complete response (CR) rates, as well as progression-free survival...

Corticosteroids Increase the Risk of Recurrent Thrombotic Events

Wednesday, June 1st, 2016
Patients with chronic inflammatory diseases, such as chronic obstructive pulmonary disease and asthma, are already at an increased risk for developing a first pulmonary...

June 2016

Early-Phase Trial Suggests CAR T-Cell Therapy Safe for Patients with Non-Hodgkin Lymphoma

Wednesday, June 1st, 2016
Results from the phase I ZUMA-1 trial presented at the AACR Annual Meeting suggest that KTE-C19, a chimeric antigen receptor (CAR), is a safe...

Novel Combination Therapy Targets Cancer Stem Cells in Multiple Myeloma

Wednesday, June 1st, 2016
Cancer stem cells (CSCs) have been identified in many diseases, including multiple myeloma (MM), but it is unclear how their frequencies change during treatment...

Spliceosome Inhibition Is a Potential Therapeutic Option for Patients with ALL and AML

Wednesday, June 1st, 2016
The novel therapeutic strategy of spliceosome targeting is a promising option for patients with acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML), including...

Study Examines Novel Second-Generation Selective Inhibitor of Nuclear Export for ALL

Wednesday, June 1st, 2016
KPT-8602, a second-generation selective inhibitor of nuclear export (SINE), demonstrated similar anti-leukemic activity and better tolerability than the first-generation SINE selinexor, according to early...

New Model Predicts Multiple Myeloma Survival Rates Will Significantly Improve in the Era of...

Wednesday, June 1st, 2016
The unprecedented number of new drug approvals in multiple myeloma will lead to an increase in the number of patients living longer with myeloma,...

Circulating Multiple Myeloma Cells a Useful, Non-Invasive Prognostic Marker for Plasma Cell Disorders

Wednesday, June 1st, 2016
In patients with plasma cell disorders, disease burden assessments and molecular subtyping are typically performed by invasive bone marrow sampling. According to a study...

SHARE